Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis

A phase 1 study of a recombinant mutant protective antigen (rPA) vaccine was conducted in 186 healthy adults aged 18 to 45 years. Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-μg dosages each, or the licensed vaccine,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bellanti, Joseph A., Lin, Feng-Ying C., Chu, Chiayung, Shiloach, Joseph, Leppla, Stephen H., Benavides, German A., Karpas, Arthur, Moayeri, Mahtab, Guo, Chunyan, Robbins, John B., Schneerson, Rachel
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2012
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272932/
https://ncbi.nlm.nih.gov/pubmed/22190398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05556-11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados